Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135667 | 0.80 | MAPK1 (0.56) | TSHRMAPTMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL9461 | 0.78 | MAPK1 (0.43) | NPC1MAPTMAPK1ALDH1A1GAA | |
| SCHEMBL1456484 | 0.77 | CYP19A1 (0.41) | RAB9AMAPK1ALDH1A1ALOX15KIF11 | |
| SCHEMBL5048108 | 0.77 | TSHR (0.39) | TSHRNPC1MAPTRAB9ACA1 | |
| SCHEMBL6776985 | 0.76 | TSHR (0.40) | TSHRACHEMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL4670012 | 0.76 | TSHR (0.40) | TSHRNPC1MAPTRAB9ACA1 | |
| SCHEMBL11152162 | 0.74 | MAPK1 (0.59) | TSHRNPC1MAPTRAB9ACA1 | |
| SCHEMBL21845090 | 0.74 | TSHR (0.57) | TSHRNPC1MAPTRAB9ACA1 | |
| SCHEMBL4669940 | 0.74 | TSHR (0.37) | TSHRNPC1MAPTRAB9ACA1 | |
| SCHEMBL4669969 | 0.74 | TSHR (0.38) | TSHRNPC1MAPTRAB9ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 729 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788353-B1 | CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2022-05-18 | — | — | EP | claimed |
| EP-1493747-B1 | PROCESS FOR PRODUCING MODIFIED PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2012-12-19 | — | — | EP | claimed |
| US-7432389-B2 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | claimed |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-21 | — | — | US | claimed |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | claimed |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1666452-A2 | Compounds to treat Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| US-7030239-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| EP-1299352-B1 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2005-12-28 | — | — | EP | claimed |
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | claimed |
| EP-1299352-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-04-09 | — | — | EP | claimed |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| EP-1265849-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2002-12-18 | — | — | EP | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | claimed |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | PSEN1, PSEN2, BACE1 | TSHR 4555/4885NPC1 24/4885MAPT 11/4885 |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BCHE | TSHR 4315/4885NPC1 31/4885MAPT 10/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | TSHR 3725/4885NPC1 64/4885MAPT 6/4885 |
| US-20060287306-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | TSHR 3979/4885NPC1 195/4885MAPT 10/4885 |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BACE1 | TSHR 4246/4885NPC1 107/4885MAPT 11/4885 |
| US-20020016320-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, CHAT | TSHR 3899/4885NPC1 16/4885MAPT 5/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | TSHR 4555/4885NPC1 24/4885MAPT 11/4885 |
| US-20060211860-A1 | Compounds for the treatment of Alzheimer's disease | PSEN2, PSEN1, CHAT | TSHR 3119/4885NPC1 130/4885MAPT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.